When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
APRE - Aprea's eprenetapopt shows treatment benefit in blood cancer study
Aprea Therapeutics Inc.
Aprea Therapeutics (NASDAQ:APRE) announces updated results from a Phase 1/2 clinical trial evaluating lead candidate APR-246 (eprenetapopt), combined with chemo agent azacitidine, in patients with TP53 mutation-positive myelodysplastic syndromes (MDS) or TP53 mutation-positive acute myeloid leukemia (AML), a genetic profile associated with a poor prognosis. The data were virtually presented at EHA.
More news on: Aprea Therapeutics, Inc., Healthcare stocks news,